51 research outputs found
Perancangan Media Komunikasi Visual Sebagai Promosi Susu Kambing Etawa Merek "Capra Latte" Di Surabaya
Full text linkSusu Kambing Etawa merek “Capra Latte” ini berdomisili di Surabaya bagian barat. Susu Kambing Etawa ini dikelolah dengan sangat bersih sehingga menjaga kemurnian dan kebersihannya. Produk yang dipasarkan adalah Susu Kambing Etawa rasa melon, stroberi dan original. Susu Kambing Etawa ini jauh lebih baik jika dibandingkan dengan susu sapi karena memiliki banyak manfaat, kandungan gizi dan tentunya tidak memiliki bau lebus khas kambing sehingga tidak menimbulkan rasa jijik disaat mengkonsumsinya. Namun seringkali terjadi salah presepsi terhadap masyarakat khususnya di Surabaya yang mengira bahwa susu kambing ini memiliki bau lebus khas kambing dan memiliki rasa tidak enak lagi pula sedikit masyarakat yang mengetahui tentang Susu Kambing Etawa merek “Capra Latte ini di Surabaya. Oleh karena itulah dibutuhkan media dan promosi yang dilakukan agar lebih memberikan edukasi dan minat terhadap para target audience dari Susu Kambing Etawa merek “Capra Latte” ini. Konsep promosi ini yaitu “Healthy Life, Healthy Drink”
An Assessment of the Impacts of Climate Variability and Change in KwaZulu-Natal Province, South Africa
Get PDFRainfall and air temperature variability pose the greatest risk to environmental change. Past trends in rainfall and air temperature facilitate projecting future climate changes for informed policy responses. We used a combination of the normalised difference vegetation index (NDVI) and observed data from 1968 to 2017 to assess changes in rainfall, moisture stress, and air temperature variability over time on bioclimatic regions of KwaZulu-Natal (KZN) Province, South Africa. Indicators used included consecutive dry days (CDDs), consecutive wet days (CWDs), very heavy rainfall days (R20), monthly maximum daily maximum air temperature (TXx), monthly minimum daily minimum air temperature (TNn), the total number of rainfall days, and monthly air temperature averages. Trends in rainfall and moisture stress are notable in different bioclimatic regions across the province. However, these trends are diverse, in general, and spatially different across and within the bioclimatic regions. Further, related rainfall indicators do not respond in the same way as would be expected. Air temperature trends were consistent with global trends and land–air temperature anomalies. Although daytime air temperatures showed a positive trend, extreme air temperature events and increases are predominant in inland regions. Night-time air temperatures showed an upward trend in most stations across KZN. Local weather-and-climate related characteristics are evolving due to climatic variability and change. The study shows that changes in climatic activities are detectable at a local level from existing historical weather data; therefore, adaptation strategies should be contextualised to respond to local and area-specific challenges
Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial].
Get PDFBACKGROUND: New strategies to increase measles and rubella vaccine coverage, particularly in low- and middle-income countries, are needed if elimination goals are to be achieved. With this regard, measles and rubella vaccine microneedle patches (MRV-MNP), in which the vaccine is embedded in dissolving microneedles, offer several potential advantages over subcutaneous delivery. These include ease of administration, increased thermostability, an absence of sharps waste, reduced overall costs and pain-free administration. This trial will provide the first clinical trial data on MRV-MNP use and the first clinical vaccine trial of MNP technology in children and infants. METHODS: This is a phase 1/2, randomized, active-controlled, double-blind, double-dummy, age de-escalation trial. Based on the defined eligibility criteria for the trial, including screening laboratory investigations, 45 adults [18-40 years] followed by 120 toddlers [15-18 months] and 120 infants [9-10 months] will be enrolled in series. To allow double-blinding, participants will receive either the MRV-MNP and a placebo (0.9% sodium chloride) subcutaneous (SC) injection or a placebo MNP and the MRV by SC injection (MRV-SC). Local and systemic adverse event data will be collected for 14 days following study product administration. Safety laboratories will be repeated on day 7 and, in the adult cohort alone, on day 14. Unsolicited adverse events including serious adverse events will be collected until the final study visit for each participant on day 180. Measles and rubella serum neutralizing antibodies will be measured at baseline, on day 42 and on day 180. Cohort progression will be dependent on review of the unblinded safety data by an independent data monitoring committee. DISCUSSION: This trial will provide the first clinical data on the use of a MNP to deliver the MRV and the first data on the use of MNPs in a paediatric population. It will guide future product development decisions for what may be a key technology for future measles and rubella elimination. TRIAL REGISTRATION: Pan-African Clinical Trials Registry 202008836432905 . CLINICALTRIALS: gov NCT04394689
A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial.
Get PDFBACKGROUND: Microneedle patches (MNPs) have been ranked as the highest global priority innovation for overcoming immunisation barriers in low-income and middle-income countries. This trial aimed to provide the first data on the tolerability, safety, and immunogenicity of a measles and rubella vaccine (MRV)-MNP in children. METHODS: This single-centre, phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial was conducted in The Gambia. To be eligible, all participants had to be healthy according to prespecified criteria, aged 18-40 years for the adult cohort, 15-18 months for toddlers, or 9-10 months for infants, and to be available for visits throughout the follow-up period. The three age cohorts were randomly assigned in a 2:1 ratio (adults) or 1:1 ratio (toddlers and infants) to receive either an MRV-MNP (Micron Biomedical, Atlanta, GA, USA) and a placebo (0·9% sodium chloride) subcutaneous injection, or a placebo-MNP and an MRV subcutaneous injection (MRV-SC; Serum Institute of India, Pune, India). Unmasked staff ransomly assigned the participants using an online application, and they prepared visually identical preparations of the MRV-MNP or placebo-MNP and MRV-SC or placebo-SC, but were not involved in collecting endpoint data. Staff administering the study interventions, participants, parents, and study staff assessing trial endpoints were masked to treatment allocation. The safety population consists of all vaccinated participants, and analysis was conducted according to route of MRV administration, irrespective of subsequent protocol deviations. The immunogenicity population consisted of all vaccinated participants who had a baseline and day 42 visit result available, and who had no protocol deviations considered to substantially affect the immunogenicity endpoints. Solicited local and systemic adverse events were collected for 14 days following vaccination. Unsolicited adverse events were collected to day 180. Age de-escalation between cohorts was based on the review of the safety data to day 14 by an independent data monitoring committee. Serum neutralising antibodies to measles and rubella were measured at baseline, day 42, and day 180. Analysis was descriptive and included safety events, seroprotection and seroconversion rates, and geometric mean antibody concentrations. The trial was registered with the Pan African Clinical Trials Registry PACTR202008836432905, and is complete. FINDINGS: Recruitment took place between May 18, 2021, and May 27, 2022. 45 adults, 120 toddlers, and 120 infants were randomly allocated and vaccinated. There were no safety concerns in the first 14 days following vaccination in either adults or toddlers, and age de-escalation proceeded accordingly. In infants, 93% (52/56; 95% CI 83·0-97·2) seroconverted to measles and 100% (58/58; 93·8-100) seroconverted to rubella following MRV-MNP administration, while 90% (52/58; 79·2-95·2) and 100% (59/59; 93·9-100) seroconverted to measles and rubella respectively, following MRV-SC. Induration at the MRV-MNP application site was the most frequent local reaction occurring in 46 (77%) of 60 toddlers and 39 (65%) of 60 infants. Related unsolicited adverse events, most commonly discolouration at the application site, were reported in 35 (58%) of 60 toddlers and 57 (95%) of 60 infants that had received the MRV-MNP. All local reactions were mild. There were no related severe or serious adverse events. INTERPRETATION: The safety and immunogenicity data support the accelerated development of the MRV-MNP. FUNDING: Bill & Melinda Gates Foundation
- …
